GPT and metabolic dysfunction-associated steatotic liver disease: ,12 Several studies demonstrated that pemafibrate significantly reduces serum Alanine Aminotransferase (ALT) and γ-Glutamyl Transpeptidase (γ-GTP) in people with type 2 diabetes and/or MASLD,13, 14, 15, 16 suggesting that it has efficacy and safety in the liver and has the potential to improve liver damage due to MASLD.